-
Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its in-house developed drug candidate, ASC47, which is designed to achieve weight loss without compromising muscle mass. The study combined ASC47 with semaglutide in a diet-induced obesity (DIO) mouse model, demonstrating superior weight loss effects compared…
-
Legend Biotech Corporation to Establish Advanced R&D Center in Philadelphia for Next-Generation Cell Therapies
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading chimeric antigen receptor (CAR) T cell therapy specialist based in China, has announced plans to establish a state-of-the-art research and development center in Philadelphia, Pennsylvania. The new 31,000 sq. ft. facility, expected to open in the third quarter of 2025, will focus on…
-
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced last week the opening of a new life sciences incubator in Shanghai, named Bayer Co.Lab Shanghai. The incubator is located in the Shanghai Innovation (SH-INNO) Park within the Zhanghiang biopharma cluster and is part of…
-
Global Researchers Call for the Revival of the Human Genome Project to Advance Precision Medicine
•
A consortium of international researchers, spearheaded by a team from China’s gene sequencing giant BGI, has issued a call to action for the revival of the Human Genome Project (HGP) in a new iteration dubbed HGP2. The initiative aims to address the burgeoning challenges facing the advancement of precision medicine…
-
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
•
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed in a London Stock Exchange filing its intention to pursue legal action against China’s genomics powerhouse BGI and its affiliates. The company alleges that BGI’s newly launched nanopore-based sequencing platform infringes upon or misappropriates Oxford…
-
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
-
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
•
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…
-
US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition
•
The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by Chinese leader Deng Xiaoping and U.S. President Jimmy Carter, has reached its sunset with the Washington government allowing it to expire on August 27, 2024. This followed two sequential 6-month extensions in August 2023 and…
-
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
•
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the…
-
American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data
•
WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered that over a thousand patents registered by Chinese inventors have received financial support from the US Defense Department, NASA, and other federal agencies. The analysis, which reviewed data from the USPTO dating back to 2010,…
-
New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate
•
The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement with global optical leader Zeiss, further strengthening their existing partnership. This collaboration will leverage the patented “Defocus Integrated Soft Contact (DISC) Technology for Myopia Management,” developed by Hong Kong Polytechnic University, to enhance Zeiss’ MyoCare…
-
HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China
•
HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the China National Intellectual Property Administration for its proprietary DNA editing system, CRISPR-Cas12i, also known as the Cas12Max system. The patent encompasses the hfCas12Max nuclease, which HuidaGene independently developed, as well as the broader CRISPR-Cas12i system…
-
Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership
•
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized a partnership with the University of Science, Malaysia (USM). The collaboration aims to enhance academic exchange and scientific translation efforts, among other initiatives. Financial details of the agreement were not disclosed. This strategic partnership builds…
-
Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration
•
Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with premier academic institutions and leading scientific research organizations. The incubator is designed to dismantle conventional silos and foster interdisciplinary collaboration among professionals, scholars, corporations, and financiers across the spectrum of “industry, academia, research, medicine, and…
-
CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab
•
China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University of Macau, marking a significant step in the biotech sector. The partnership, formalized with a signing ceremony at the Guangdong-Macao in-depth cooperation zone in Hengqin, aims to leverage the university’s cutting-edge research capabilities and CNBG’s…
-
CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine
•
CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration…
-
Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation
•
Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park located in Beijing E-Town, during the Boao Forum for Asia. The initiative aims to establish a hub for high-energy innovation resources, support the development of high-value innovative products, and foster an efficient innovation ecosystem. Bio…
-
China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing
•
China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome Editing Research, establishing a framework to regulate such activities and ensure their responsible development. The guidelines place a stringent prohibition on germline editing, which involves genetic modifications that could be passed down to future generations.…
-
Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits
•
Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on the neurological and psychiatric effects of the obesity/type 2 diabetes (T2D) drug semaglutide, marketed as Ozempic and Wegovy. The first-of-its-kind study scrutinized the outcomes within a year of the first dose, focusing on T2D patients.…
-
Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery
•
Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in China, has entered into a strategic partnership with the Innovation Center of Yangtze River Delta, Zhejiang University. This high-capacity innovation platform is a joint initiative by Zhejiang University and Jiashan county in Jiaxing city of…
